Inventor · disambiguated record
Jason J. Wu
Also filed as: WU JASON · WU JASON J · WU JASON JINZI
6 granted patents·8 pending applications·48 citations·filing 2009–2025
84Inventor score
Files withNORDSIEK MICHAEL T6GRACEWAY PHARMACEUTICALS LLC4MEDICIS PHARMACEUTICAL CORP2ASCLETIS BIOSCIENCE CO LTD1BROAD INST INC1
Top patents by PatentIndex Score
14 records- 0191US8299109B2Method of treating actinic keratosis with 3.75% imiquimod creamNORDSIEK MICHAEL T·Filed 2011·Granted Oct 30, 2012·17 cites·15 claims
- 0290US8222270B22×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimodNORDSIEK MICHAEL T·Filed 2011·Granted Jul 17, 2012·13 cites·18 claims
- 0389US8236816B22×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimodNORDSIEK MICHAEL T·Filed 2011·Granted Aug 7, 2012·12 cites·18 claims
- 0484US9370509B22×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimodNORDSIEK MICHAEL T·Filed 2012·Granted Jun 21, 2016·5 cites·15 claims
- 0576US10238644B22×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimodMEDICIS PHARMACEUTICAL CORP·Filed 2016·Granted Mar 26, 2019·1 cites·20 claims
- 0669US11318130B22x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimodMEDICIS PHARMACEUTICAL CORP·Filed 2019·Granted May 3, 2022·0 cites·15 claims
- 0768US2011021555A1Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratosesGRACEWAY PHARMACEUTICALS LLC·Filed 2009·Application pending·0 cites
- 0861US2025352670A1Delivering genes to the brain endothelium to treat lysosomal storage disorder-derived neuropathologyBROAD INST INC·Filed 2025·Application pending·0 cites
- 0959US2012329823A1Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal wartsNORDSIEK MICHAEL T·Filed 2012·Application pending·0 cites
- 1057US2011263636A13 x 3 x 3 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMODGRACEWAY PHARMACEUTICALS LLC·Filed 2011·Application pending·0 cites
- 1157US2011263637A1Up to six weeks dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimodGRACEWAY PHARMACEUTICALS LLC·Filed 2011·Application pending·0 cites
- 1253US2025340529A1Heterocyclic Compounds as Immunomodulators of PD-L1 InteractionsASCLETIS BIOSCIENCE CO LTD·Filed 2021·Application pending·0 cites
- 1353US2011207766A1Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal wartsGRACEWAY PHARMACEUTICALS LLC·Filed 2010·Application pending·0 cites
- 1443US2011319811A1Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosisNORDSIEK MICHAEL T·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jason J. Wu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →